TNF-alpha blockade with infliximab in a patient with lupus erythematosus profundus

Acta Dermato-Venereologica

Volumn 92, Issue 4, 2012, Pages 401-403

  Günther, Claudia ^a   Aringer, Martin ^a   Lochno, Marlene ^a   Kämmerer, Eva ^a   Bauer, Andrea ^a   Wozel, Gottfried ^a   Meurer, Michael ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADIPOCYTE; ADULT; ARTHRITIS; CASE REPORT; CHOLELITHIASIS; DEPRESSION; ECHOCARDIOGRAPHY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAIR LOSS; HISTOLOGY; HUMAN; IMMUNOFLUORESCENCE; INFLUENZA VACCINATION; LETTER; MYOSITIS; PAIN; PERIORBITAL EDEMA; PRIORITY JOURNAL; RASH; REMISSION; SKIN CALCIFICATION; SKIN DEFECT; SKIN NECROSIS; SKIN ULCER; SUBCUTANEOUS FAT; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOPSY; FEMALE; HUMANS; PANNICULITIS, LUPUS ERYTHEMATOSUS; SEVERITY OF ILLNESS INDEX; SKIN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863463409     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-1262     Document Type: Letter

References (15)

1. Fraga J, Garcia-Diez A. Lupus erythematosus panniculitis. Dermatol Clin 2008; 26: 453-463.
2. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982; 216: 429-431.
3. Aringer M, Feierl E, Steiner G, Stummvoll GH, Hofler E, Steiner CW, et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 2002; 11: 102-108.
4. Zampieri S, Alaibac M, Iaccarino L, Rondinone R, Ghirardello A, Sarzi-Puttini P, et al. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis 2006; 65: 545-548.
5. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004; 50: 3161-3169.
6. Hiepe F, Bruns A, Feist E, Burmester G. Successful treat ment of a patient suffering from a refractory subacute cutaneous lupus erythematosus (SCLE) with blockers of tumor necrosis factor α. Arthritis Rheum 2004; 50: 413.
7. Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol 2006; 54: S139-S142.
8. Costenbader KH, Kim DJ, Peerzada J, Lockman S, Nobles-Knight D, Petri M, et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2004; 50: 849-857.
9. Cyran S, Douglass MC, Silverstein JL. Chronic cutaneous lupus erythematosus presenting as periorbital edema and erythema. J Am Acad Dermatol 1992; 26: 334-338.
10. Krengel S, Kolmel KF. Differentialdiagnostik bei Lidschwellungen. Hautarzt 1996; 47: 2-19.
11. Franke W, Kuhn A, Megahed M, Krutmann J, Ruzicka T, Lehmann P. Periorbitales Ödem als Initialsymptom eines Lupus erythematodes profundus. Kasuistik und Diskussion der Literatur. Hautarzt 1999; 50: 889-892.
12. Pisetsky DS. Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 2000; 43: 2381-2382.
13. de Bandt M, Sibilia J, Le Loët X, Prouzeau S, Fautrel B, Marcelli C, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7: R545-R551.
14. Kuhn A, Gensch K, Stander S, Bonsmann G. Kutaner Lupus erythematodes. Teil 2: Diagnostik und Therapie. Hautarzt 2006; 57: 345-348.
15. Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009; 48: 1451-1454.